CDK7 might also be an attractive target in MYC‐driven tumors: indeed, the covalent CDK7 inhibitor THZ1 [237] disproportionally repressed super‐enhancer regulated genes, including MYC, MYCN and MYCL in diverse cancer‐derived cell lines [238, 239]. The gene discussed is MYCL; the disease is cancer.